Recursion Pharmaceuticals Stock (NASDAQ: RXRX)

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

movers image

News

Intraday Update

Markets

Movers

Trading Ideas

ALLO

HEES

INTC

MRNA

OSCR

RXRX

SMCI

ZLAB

Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday

Uber Weride

Equities

Mid Cap

AXSM

CRSP

MKGAF

MKKGY

NVDA

SWTX

TEVA

VNET

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?

BCTX

DRUG


Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to keep their doors open during a pre-revenue period while they develop drug treatments and

Biotechs on the Brink: 2 Stocks With Huge Potential

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals Inc

Dividends

AESI

Atlas Energy Solutions Increases Quarterly Dividend From $0.24 To $0.25

WIIM

ACVA

ACV Auctions shares are trading lower following a Q4 EPS miss.

ONE Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGS#NYSE">OGS</a>) reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.33 by 0.75 percent. The company reported quarterly sales of $630.70 million which missed the analyst consensus estimate of $973.58 million by 35.22 percent. This is a 4.09 percent increase over sales of $605.92 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

ONE Gas Q4 2024 Adj EPS $1.34 Beats $1.33 Estimate

Inseego (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) sees Q1 sales of $30.000 million-$33.000 million vs $41.40 million analyst estimate.

Guidance

INSG

Inseego Sees Q1 Sales $30.000M-$33.000M vs $41.40M Est

RELY

Remitly Global shares are trading higher after the company reported better-than-expected Q4 financial results.

CHMG

Chemung Financial Increases Quarterly Dividend From $0.31 To $0.32

CVNA

Carvana shares are trading lower. The company reported Q4 financial results.

Inseego (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(0.31) by 296.77 percent. This is a 3.91 percent increase over losses of $(1.28) per share from the same period last year. The company reported quarterly sales of $48.09 million which beat the analyst consensus estimate of $45.57 million by 5.53 percent. This is a 12.47 percent increase over sales of $42.75 million the same period last year.

Inseego Q4 EPS $(1.23) Misses $(0.31) Estimate, Sales $48.09M Beat $45.57M Estimate

On Wednesday, Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) launched Majorana 1, making its <a target="_blank" href="https://www.benzinga.com/topic/quantum-computing" rel="noreferrer noopener">quantum chip debut</a> powered by a new Topological Core architecture that it expects to realize quantum computers capable of solving meaningful, <a target="_blank" href="https://news.microsoft.com/source/features/ai/microsofts-majorana-1-chip-carves-new-path-for-quantum-computing/" rel="noreferrer noopener">industrial-scale problems in years</a>.
The chip leverages topoconductor, a material which can observe and control Majorana particles to produce more reliable and scalable qubits, which are the building blocks for quantum computers.
Topoconductors and Microsoft&#8217;s new type of chip&nbsp;offer a path to developing quantum systems that can scale to a million qubits and tackle the most complex industrial and societal problems.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/emerging-markets/25/02/43815333/muddy-waters-carson-block-warns-against-chinese-stocks-despite-recent-market-surge-report" rel="noreferrer noopener">Muddy Waters&#8217; Carson Block Warns Against Chinese Stocks Despite Recent Market Surge: Report</a>
This new architecture offers a clear path to fit a million qubits on a single chip that can fit in the palm of one&#8217;s hand, delivering solutions like breaking down microplastics into harmless byproducts or inventing self-healing materials for construction, manufacturing, or healthcare.
The topoconductor, or topological superconductor, is a unique material category that can create a topological state that can produce a more stable qubit that is fast, small, and digitally controlled.
The topoconductor required developing an entirely new materials stack made of indium arsenide and aluminum, much of which Microsoft designed and fabricated atom by atom.
Microsoft aimed to coax new quantum particles called Majoranas into existence and take advantage of their unique properties to reach the next horizon of quantum computing.&nbsp;
The world&#8217;s first Topological Core, powering the Majorana 1, is reliable by design. It incorporates error resistance at the hardware level, making it more stable.
The Microsoft team&#8217;s new measurement approach enables qubits to be controlled digitally.
Microsoft has placed eight topological qubits on a chip designed to scale to one million.
That approach led the Defense Advanced Research Projects Agency (DARPA) to include Microsoft in a program to evaluate innovative quantum computing technologies.&nbsp;&nbsp;
In addition to making its quantum hardware, Microsoft has partnered with Quantinuum and Atom Computing to reach&nbsp;scientific and engineering breakthroughs&nbsp;with today&#8217;s qubits.
Now, Azure Quantum offers a&nbsp;suite of integrated solutions&nbsp;that allow customers to leverage these leading AI, high-performance computing, and quantum platforms in Azure to advance scientific discovery.
Last December, Alphabet Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google announced its&nbsp;<a target="_blank" href="https://www.benzinga.com/tech/24/12/42397333/google-quantum-ais-new-willow-chip-can-do-in-minutes-that-supercomputers-would-take-10-septillion-years" rel="noreferrer noopener">quantum chip&nbsp;Willow</a>. The company said Willow could reduce errors exponentially as it scaled up&nbsp;using&nbsp;more&nbsp;qubits.
In November,&nbsp;Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) tapped Quantum AI to drive the development of next-generation&nbsp;quantum computing devices to reduce week-long processes and advance quantum hardware innovation.
Google&nbsp;looks to introduce&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43552657/google-to-launch-commercial-quantum-computing-applications-in-five-years-challenges-nvdia-on-the-timeline" rel="noreferrer noopener">commercial quantum computing applications</a> within&nbsp;the next five years, challenging&nbsp;Nvidia chief&nbsp;Jensen Huang&#8217;s&nbsp;20-year prediction.
Price Action: MSFT stock closed up by 1.25% to $414.77 on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43793464/robinhood-to-expands-crypto-offerings-in-singapore-in-push-for-global-growth" target="_blank" rel="noreferrer noopener">Robinhood To Expands Crypto Offerings In Singapore In Push For Global Growth</a></li>
</ul>

Short Sellers

Tech

GOOG

GOOGL

MSFT

Microsoft Joins Quantum Computing Battle with Majorana 1, Challenging Google, Nvidia's Advances

ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $159.51 million which beat the analyst consensus estimate of $155.91 million by 2.31 percent. This is a 34.75 percent increase over sales of $118.38 million the same period last year.

ACV Auctions Q4 EPS $(0.16) Misses $(0.14) Estimate, Sales $159.51M Beat $155.91M Estimate

Openlane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAR#NYSE">KAR</a>) is looking for FY2025 Adj EPS of $0.90-$1.00 vs $0.96 analyst estimate..

Openlane Sees FY2025 Adj EPS $0.90-$1.00 vs $0.96 Est

Jackson Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JXN#NYSE">JXN</a>) reported quarterly earnings of $4.65 per share which missed the analyst consensus estimate of $4.88 by 4.71 percent. This is a 83.79 percent increase over earnings of $2.53 per share from the same period last year.

Jackson Finl Q4 2024 Adj EPS $4.65 Misses $4.88 Estimate

Openlane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAR#NYSE">KAR</a>) is looking for FY2025 GAAP EPS of $0.38-$0.48 vs $0.69 analyst estimate..

Openlane Sees FY2025 GAAP EPS $0.38-$0.48 vs $0.69 Est

CWAN

Clearwater Analytics Holdings Sees FY25 Revenue $535.5M-$542M Vs $533.347M Est.

New York Mortgage Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYMT#NASDAQ">NYMT</a>) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $0.05 by 1020 percent. This is a 231.43 percent decrease over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $26.71 million which beat the analyst consensus estimate of $20.77 million by 28.60 percent. This is a 58.99 percent increase over sales of $16.80 million the same period last year.

NYMT

New York Mortgage Trust Q4 GAAP EPS $(0.46) Misses $0.05 Estimate, Sales $26.71M Beat $20.77M Estimate

Clearwater Analytics Holdings Sees Q1 Revenue $125M Vs $122.972M Est.

Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.92 by 13.04 percent. This is a 30 percent increase over earnings of $0.80 per share from the same period last year. The company reported quarterly sales of $920.96 million which beat the analyst consensus estimate of $912.32 million by 0.95 percent. This is a 5.01 percent increase over sales of $877.01 million the same period last year.

CAKE

Cheesecake Factory Q4 Adj $1.04 Beats $0.92 Estimate, Sales $920.96M Beat $912.32M Estimate

Openlane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAR#NYSE">KAR</a>) reported quarterly earnings of $0.21 per share which met the analyst consensus estimate. This is a 31.25 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $455.00 million which beat the analyst consensus estimate of $420.44 million by 8.22 percent. This is a 12.04 percent increase over sales of $406.10 million the same period last year.

Openlane Q4 Adj $0.21, Inline, Sales $455.00M Beat $420.44M Estimate

The dividend on the common stock will be payable on March 20, 2025, to shareholders of record at the close of business on March 11, 2025.

Jackson Increases Q1 Common Stock Dividend By 14% From $0.70 To $0.80 Per Share

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) reported quarterly earnings of $3.43 per share which beat the analyst consensus estimate of $3.42 by 0.29 percent. This is a 0.87 percent decrease over earnings of $3.46 per share from the same period last year. The company reported quarterly sales of $2.04 billion which met the analyst consensus estimate. This is a 1.22 percent decrease over sales of $2.07 billion the same period last year.

ICLR

Icon Q4 2024 Adj EPS $3.43 Beats $3.42 Estimate, Sales $2.04B Inline

Press Releases

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Small Cap

Opinion

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Health Care

Economics

Altitude Lab Startups Raise $154M in Capital

Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City

Comments

Recursion Pharmaceuticals

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga